Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

Taichung Veterans General Hospital100 enrolled

Overview

This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)Drug-Related Side Effects and Adverse Reactions (MeSH Term)Egfr Tyrosine Kinase Inhibitor Cardiotoxicity

Interventions

EGFR-TKIDRUG

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line.

EGFR tyrosine kinase inhibitorOTHER

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with advanced or recurrent EGFR-mutant NSCLC receiving EGFR-TKI treatment Exclusion Criteria: * NIL

Locations (1)

Taichung Veterans General Hospital

Taichung, Taiwan

Outcomes

Primary Outcomes

The incidence of cancer therapy-related cardiac dysfunction after treatment with EGFR tyrosine kinase inhibitors.

Cancer therapy-related cardiac dysfunction was defined as a left ventricular ejection fraction of less than 50% and an absolute reduction in LVEF of more than 10% from baseline.

Time frame: From enrollment to 2 years after initiating EGFR tyrosine kinase inhibitor treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.